Rx-to-OTC switching boom continues as consumers, insurance providers, and U. S. government vigorously support switching as a means for decreasing overall cost of healthcare

Rx-to-OTC switching boom continues as consumers, insurance providers, and U. S. government vigorously support switching as a means for decreasing overall cost of healthcare.



(PRWEB) August 26, 2004



Research and Markets announces the addition of "Rx to OTC Switch 2003: Leading Candidate Screening and Strategic Analysis" to its offerings.



The sales revenue for over-the-counter (OTC) products amounted to over $30 billion in 2002, with approximately one third attributed to products that have switched from prescription (Rx)to OTC status. Front Line predicts an Rx-to-OTC switching boom over the next five years as consumers, insurance providers, and the U. S. government vigorously support switching as a means for decreasing the overall cost of healthcare.



Rx-to-OTC switching is a deliberate, strategic move that pharmaceutical manufacturers employ when anticipating patent expiration of their products or competition from an approaching new drug class. Additionally, as with Schering-PloughÂ’s Claritin (loratadine), some companies are forced to switch by the U. S. government, further demonstrating the need for sound and preemptive switching strategies.



This report includes an in-depth analysis of current Rx-to-OTC trends, case studies of historical switches, the identification of leading candidates most likely to switch by 2008, and strategic switching strategy options. Also included is a detailed description of FLOSSTM(Front Line Over-the-Counter Switching Screen), Front LineÂ’s proprietary screening model, that was used to assess the leading revenue generating drugs and their likelihood of successfully switching to OTC status.



For a thorough analysis of this important market, this report:



-examines various rationales behind Rx-to-OTC switching



-thoroughly discusses past Rx-to-OTC switches



-analyzes current trends and how they will effect the future of Rx-to-OTC switching



-identifies leading Rx-to-OTC switching candidates by 2008 using a proprietary screening model



-includes in-depth description of screening model development and use



-evaluates risks and challenges facing the industry and proposes potential switching strategies



For a complete index of this report click on http://www. researchandmarkets. com/reports/222238 (http://www. researchandmarkets. com/reports/222238)



About Research and Markets Ltd.



Research and Markets Ltd. are Europe's largest resource for market research. R&M distribute thousands of major research publications from the world's leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.



For additional information on ResearchandMarkets. com, their range of reports or their value-added services, visit their web site at http://www. researchandmarkets. com (http://www. researchandmarkets. com) or mailto:press@researchandmarkets. com

You have read this article health with the title Rx-to-OTC switching boom continues as consumers, insurance providers, and U. S. government vigorously support switching as a means for decreasing overall cost of healthcare. You can bookmark this page URL https://ysagabriellechong.blogspot.com/2010/02/rx-to-otc-switching-boom-continues-as.html. Thanks!